A phase II study of weekly paclitaxel and doxifluridine combination chemotherapy for advanced/recurrent gastric cancer

Anticancer Research

Volumn 31, Issue 1, 2011, Pages 287-291

  Takeyoshi, Izumi ^a   Makita, Fujio ^b   Tanahashi, Yoshifumi ^c   Iwazaki, Shigeru ^d   Ogawa, Tetsushi ^e   Tomizawa, Naoki ^e   Nakamura, Seiji ^f   Ishikawa, Hitoshi ^g   Ohya, Toshihiro ^h   Kakinuma, Shinichi ⁱ   Nakagami, Katsunao ^j   Sato, Yoshihiro ^k   Koyano, Tetsuya ^l   Roppongi, Takashi ^m   Izumi, Masaru ⁿ   Kobayashi, Junya ^g   Kawate, Susumu ^a   Sunose, Yutaka ^a   Kobayashi, Mitsunobu ^b   Yamada, Tatsuya ^a   Sakamoto, Ichiro ^a   more..

^a GUNMA UNIVERSITY   (Japan)

^b Shibukawa Medical Center   (Japan)

^c Shibukawa General Hospital   (Japan)

^d Tatebayashi Kosei Hospital   (Japan)

^e MAEBASHI RED CROSS HOSPITAL   (Japan)

^f Takasaki Hospital   (Japan)

^g Fujiyoshida Municipal Hospital   (Japan)

^h Ojiya General Hospital   (Japan)

ⁱ Department of Surgery   (Japan)

^j Ogawa Red Cross Hospital   (Japan)

^k Department of Surgery   (Japan)

^l Cardiovascular Hospital of Central Japan   (Japan)

^m Department of Surgery   (Japan)

ⁿ Suto Hospital   (Japan)

more..

Author keywords

Chemotherapy; Doxifluridine; Gastric cancer; Paclitaxel; Thymidine phosphorylase

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; DOXIFLURIDINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURGERY; CHEMOTHERAPY INDUCED EMESIS; DIARRHEA; DRUG FEVER; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MYALGIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SENSORY NEUROPATHY; SIDE EFFECT; STOMACH CANCER; STOMATITIS; THROMBOCYTE COUNT; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DIFFERENTIATION; FEMALE; FLOXURIDINE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79851471037     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Pyrhonen S, Kuitunen T, Nyandoto P and Kouri M: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71: 587-591, 1995.
2. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA and Rausch M: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72: 37-41, 1993. (Pubitemid 23182046)
3. Glimelius B, Hoffman K, Haglund U, Nyren O and Sjoden PO: Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 5: 189-190, 1994. (Pubitemid 24062577)
4. Enjoji A; Nagasaki Digestive Organ Cancer Chemotherapy Study Group Japan: Combination chemotherapy of 5-fluorouracil and low-dose cisplatin in advanced and recurrent gastric cancer: a multicenter retrospective study in Nagasaki, Japan. Anticancer Res 22: 1135-1139, 2002.
5. Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, Sakata Y and Hyodo I: Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 17: 319-323, 1999. (Pubitemid 29022409)
6. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J and Ohtsu A: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomaised phase 3 study. Lancet Oncol 10: 1063-1069, 2009.
7. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H and Takeuchi M: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9: 215-221, 2008.
8. Ohtsu A, Boku N, Tamura F, Muro K, Shimada Y, Saigenji K, Akazawa S, Kitajima M, Kanamaru R and Taguchi T: An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol 21: 416-419, 1998. (Pubitemid 28366916)
9. Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H, Miyata Y and Taguchi T: Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 12: 1133-1137, 2001. (Pubitemid 32834495)
10. Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R and Mansfield PF: Phase II study of taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 4: 269-274, 1998.
11. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T and Ishitauka H: Induction of thymidine Phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4: 1013-1019, 1998. (Pubitemid 28183404)
12. Miwa M, Cook A and Ishitsuka H: Enzymatic cleavage of various fluorinated pyrimidine nucleosides to 5-fluorouracil and their antiproliferative activities in human and murine tumor cells. Chem Pharm Bull (Tokyo) 34: 4225-4232, 1986. (Pubitemid 17201156)
13. Takeyoshi I, Makita F, Tanahashi Y, Yokomori T, Iwazaki S, Kawashima Y, Iwanami K, Yamada T, Kawate S, Hamada K, Sunose Y, Yoshida M, Horiguchi J, Iesato H, Kobayashi M and Morishita Y: A combination phase I study of weekly paclitaxel and doxifluridine in advanced gastric cancer patients. Anticancer Res March 25: 1291-1296, 2005. (Pubitemid 40546804)
14. Kodera Y, Ito S, Mochizuki Y, Fujitake S, Koshikawa K, Kanyama Y, Matsui T, Kojima H, Takase T, Ohashi N, Fujiwara M, Sakamoto J and Nakano A: A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study). Anticancer Res 27: 2667-2672, 2007.
15. Matsuda G, Kunisaki C, Makino H, Fukahori M, Kimura J, Sato T, Oshima T, Nagano Y, Fujii S, Takagawa R, Kosaka T, Ono HA, Akiyama H and Ichikawa Y: Phase II study of weekly paclitaxel as a second-line treatment for S-1 refractory advanced gastric cancer. Anticancer Res 29: 2863-2868, 2009.
16. Morowaki T, Hyodo I, Nishina T, Hirao K, Tsuzuki T, Hidaka S, Kajiwara T, Endo S, Nasu J, Hirasaki S, Matsumoto T and Kurita A: A phase I study of doxifluridine combined with weekly paclitaxel for metastatic gastric cancer. Cancer Chemothr Pharmacol 56: 138-144, 2005. (Pubitemid 40894630)
17. Yoshino S, Oka M, Hazama S, Hamano K, Hayashi H, Hasegawa H, Yamamoto T and Katoh T: A combination phase I study of weekly paclitaxel and 5′-DFUR in patients with unresectable or recurrent gastric cancer in an outpatient setting. Meeting Proc Am Soc Clin Oncol (ASCO) 23: p. 369, Abstract No.4228, 2004.
18. Takiuchi H, Goto M, Imamura H, Furukawa H, Imano M, Imamoto H, Kimura Y, Ishida H, Fujitani K, Narahara H and Shimokawa T: Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302). Jpn J Clin Oncol 38: 176-181, 2008. (Pubitemid 351419740)
19. Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, Houghton M and Urrea P: Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 23: 6957-6965, 2005.